United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Nagpur Oral Solid Dosage Facility from July 3, 2023 to July 11, 2023. The inspection closed with issuance of a Form-483 with two observations.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.